1863 First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (neo)adjuvant trastuzumab. (September 2015) - Vaglica, M.; Lambertini, M.; Ferreira, A.; Poggio, F.; Puglisi, F.; Sottotetti, F.; Montemurro, F.; Poletto, E.; Pozzi, E.; Risi, E.; Lai, A.; Zanardi, E.; et al.